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Objectives: Promoter methylation of some cancer-related genes may occur in many cancers and also in
their precancerous lesions. This study examined adenomatous polyposis coli (APC), glutathione S-
transferase, pi-class (GSTP1), prostaglandin-endoperoxide synthase 2 (PTGS2), and retinoic acid receptor
beta (RARB) genes to assess if they are sensitive methylation markers when used to detect high-grade
squamous intraepithelial lesions (HSIL) and early cancer in cervical tissues.
Materials and methods: DNA was obtained from 11 HSILs, 20 samples of squamous cell carcinoma (SCC)
in situ (SCIS), and 16 samples of early SCC. The promoter methylation status of the selected genes was
assessed using a methylation-speciﬁc polymerase chain reaction (MSP).
Results: One SCC sample was noninformative for all four genes. Five of the remaining samples were
informative for three genes and 41 samples for all four genes. The rate of detection rate of at least one
gene in the SCC group (60.0%, 9/15) was signiﬁcantly higher than in the HSIL group (27.2%, 3/11) and the
SCIS group (15.0%, 3/20) group (p ¼ 0.025). The highest detection rate for PTGS2 was seen in the SCIS
group (11.1%, 2/18) with the highest rates for APC (20.0%, 3/15), GSTP1 (7.1%, 1/14), and RARB (28.6%, 4/14)
in the SCC group. Only RARB exhibited a signiﬁcantly higher detection rate in the SCC group than in the
other two groups (p ¼ 0.027).
Conclusion: The results conﬁrmed that promoter methylation of APC, GSTP1, PTGS2, and RARB is not
prevalent in cervical tissues with HSIL or cancer. They are not sensitive methylation markers when used
to detect these lesions in cervical tissues.
Copyright © 2014, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
It is evident that adequate screening combinedwith appropriate
treatment of preinvasive lesions could signiﬁcantly decrease the
incidence and mortality of cervical cancer [1]. Screening programs
have used broadly morphological assessment of cervical scrapings.
Nonattendance is the primary limiting factor for the effectiveness
of such screening programs. Moreover, invasive cervical cancer stillChi Mei Medical Center, 901,
an. Tel.: þ886 6 3354950;
Tzeng).
elief Tzu Chi Foundation. Publisheoccurs in women who have access to cancer screening and treat-
ment services. The main causes of invasive cervical cancer in this
patient group can be attributed to false-negative Pap smears and to
poor follow-up of abnormal results [2].
Theoretically, the solution to these problems is to develop a
sensitive screening test that could reliably identify self-sampling
cervicovaginal samples with high-grade dysplasia or more severe
disease [3]. Because cervicovaginal materials often contain a large
amount of normal vaginal cells, the few abnormal cells might easily
be missed in a morphology-based screening test. Screening for
high-risk human papillomavirus (HPV) infection is highly sensitive,
but not speciﬁc, for this purpose, because in most patients, a pos-
itive HPV test result indicates a transient infection rather than a risk
of eventual invasive cervical cancer [4,5].d by Elsevier Taiwan LLC. All rights reserved.
Table 1
Gene symbol, name, primer sequences, annealing temperature (Ta) for the
methylation-speciﬁc PCR, and sizes of PCR product.
Gene
symbol
Primer sequence Product
(bp)
Ta
(C)
APC UF: GTGTTTTATTGTGGAGTGTGGGTT
UR: CCAATCAACAAACTCCCAACAA
108 58
MF: TATTGCGGAGTGCGGGTC
MR: TCGACGAACTCCCGACGA
98 58
GSTP1 UF: GATGTTTGGGGTGTAGTGGTTGTT 97 58
MF: TTCGGGGTGTAGCGGTCGTC
MR: GCCCCAATACTAAATCACGACG
91 58
PTGS2 UF: TTTAATTTTATTTGTTTTAGTTTGTTTTGATGTGATTT
TTTTG
UR: TCCAAAAATCTAAACAACCCTAAAATCCAAAAACA
136 56
MF: TTAATTTTATTCGTTTTAGTTTGTTTCGACGTGATT
TTTTC
MR: TAAACGACCCTAAAATCCGAAAACG
125 56
RARB UF: TTGAGAATGTGAGTGATTTGA
UR: AACCAATCCAACCAAAACAA
146 54
MF: TCGAGAACGCGAGCGATTCG
MR: GACCAATCCAACCGAAACGA
146 58
APC ¼ adenomatous polyposis coli; GSTP1 ¼ glutathione S-transferase, pi-class;
PTGS2 ¼ prostaglandin-endoperoxide synthase 2; RARB ¼ retinoic acid receptor
beta.
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epigenetic alterations is being widely considered as another
attractive approach, because such alterations often increase grad-
ually from precancerous lesions to invasive cancer [6]. Among these
putative alterations, detection of aberrant methylation seems to
have the greatest potential in screening tests to detect cancer at the
precancerous and early invasive stages [7]. The excellent stability of
methylated DNA in most clinical specimens allows them to be
analyzed using a variety of detection methods [8].
In addition to the methodology used to detect methylation
markers, the genes selected for the test are also important in
determining the usefulness of a screening program. Theoretically, in
the search for these marker genes, the simplest strategy would be a
two-stage approach. The ﬁrst stage of research focuses on ﬁnding
candidate genes that can detect the targeted lesion with high
sensitivity. From these candidate marker genes, the second-stage
study is designed to verify the gene(s) that can distinguish test
samples with or without the targeted lesion with high speciﬁcity.
Genome-wide analysis seems to be an effective way to identify
some geneswith high sensitivity and speciﬁcity. However, the genes
identiﬁed so far by different research teams based on this approach
have not shown any overlap in any gene [9e13]. An alternative
approach used in this study was to search the PubMeth database, in
which the reported detection frequencies of numerous genes with
promoter methylation in human cancers are collected [14]. Among
the geneswith a reported prevalence ranging from60% to 80%, there
were at least four genes reported in cervical cancers with detection
frequencies that varied widely or were reported in only a single
study. These genes were adenomatous polyposis coli (APC), gluta-
thione S-transferase, pi-class (GSTP1), retinoic acid receptor beta
(RARB), and prostaglandin-endoperoxide synthase 2 (PTGS2)
[15e20]. This ﬁrst-stage study tried to elucidate the methylation
prevalence of these four genes in cervical tissues with high-grade
squamous intraepithelial lesions (HSIL) up to early cancer. Based
on detection rates determined by methylation-speciﬁc polymerase
chain reaction (MSP), the goal of this study was to verify if any of
these four genes has a detection frequency > 60%, thus meriting
further evaluation in a second-stage study.
2. Materials and methods
2.1. Sample selection
From the pathological ﬁle at Chi Mei Medical Center, Tainan,
Taiwan, all cervical specimens resected through conization or
hysterectomy between 2004 and 2006 were reviewed. There were
a total of 47 samples with an adequate amount of the targeted
lesion, including 11 samples with HSIL, 20 with squamous cell
carcinoma (SCC) in situ (SCIS), and 16 with invasive SCC at an early
stage (pT1a2 or pT1b1). The morphological diagnostic criteria fol-
lowed those deﬁned by the World Health Organization, while the
pathological staging adhered to the deﬁnition of the American Joint
Committee on Cancer/International Union for Cancer Control. The
Institutional Review Board of Chi Mei Medical Center reviewed and
approved this study (09912-004).
In tissuesections stainedwithhematoxylinandeosin, areasof the
representative parafﬁn-embedded tissue blocks rich in the above-
targeted lesions were punched out using a bone marrow punch in-
strument (BM 11-10, Gallini Medical Devices, Mirandola, Italy). Each
selected tissue core was 3 mm in diameter and 2 mm thick.
2.2. DNA preparation
The punched tissues were ﬁrst treated by xylene to remove the
parafﬁn, followed by washes with 100% alcohol. The tissue sampleswere then incubated in a mixture containing 500 mL of the cell lysis
solution from the Puregene kit (D-50K2, Minneapolis, MN, USA)
and 5 mL of proteinase K solution (Sigma-Aldrich, St. Louis, MO,
USA; 10 mg/mL in 10mM Tris, pH 7.8, 5mM EDTA, and 0.5% sodium
dodecyl sulfate) at 55C overnight or longer if needed. Subsequent
DNA isolation followed the Puregene procedures using D-50K3
solution for protein precipitation, 100% isopropanol to form DNA
pellets, and 70% alcohol for a ﬁnal washing. After vacuum drying,
the DNA pellet was dissolved in an appropriate amount of 1 X Tris-
EDTA (TE) buffer and stored at 20C for long-term storage. The
DNA concentration was determined using a ﬂuorometer (Hoefer
Scientific Instruments, San Francisco, CA, USA).
2.3. MSP
Prior to the analysis, DNA samples were modiﬁed using bisulﬁte
treatment to convert unmethylated (but not methylated) cytosines
to uracil using protocols modiﬁed from those reported by other
researchers [21,22]. Brieﬂy, 1 mg of each DNA sample was treated in
0.3M sodium hydroxide (NaOH) at 37C for 30 minutes and then
incubated in 3.0M sodium bisulﬁte (NaHSO3; S8890; Sigma-
Aldrich, St. Louis, MO, USA) and 0.5 M hydroquinone (C6H4(OH)2;
H9003; Sigma-Aldrich) at 55C overnight. After desalination using
the Wizard DNA Clean-Up System (Promega, Madison, WI, USA),
samples were denatured using 0.3 M NaOH at room temperature
for 5 minutes and then neutralized using 2.5 M ammonium acetate
(NH4C2H3O2). Subsequently, the DNA in the sample suspensionwas
precipitated using 100% alcohol, followed by washing with 75%
alcohol and then air drying. Finally, the DNA pellet of each sample
was dissolved in 50 mL of 1 X TE and stored at 4C for several weeks
or at 20C for long-term storage.
These modiﬁed DNA samples were then subjected to poly-
merase chain reaction (PCR) using either unmethylated (Um)
primers or methylated (M) primers to amplify the corresponding
unmethylated and methylated promoter sequences, respectively.
Table 1 lists the sequences of all primers used in this study,
coupled with the related annealing temperatures and PCR product
sizes. Each test was performed in a 30 mL PCR mixture, containing
1X PCR buffer (Green GoTaq Flexi Buffer, Promega), 0.6 U GoTaq
Host Start Polymerase (Promega), 75 ng bisulﬁte modiﬁed DNA,
and 100mM of both primers. The PCR started with an initial
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for 45 seconds, 55C for 45 seconds, 72C for 1 minute, and then a
ﬁnal extension at 72C for 10 minutes. Finally, the PCR products
were subjected to electrophoresis using 5% polyacrylamide gels
and then visualized under ethidium bromide staining and ultra-
violet illumination.
Each PCR experiment included two control DNA samples, in
which the whole genomic sequences were either universally
methylated (positive control) or unmethylated (negative control).
The methylated (positive) control DNA was prepared by treating
lymphocyte DNA with M.SssI (New England Biolabs, Beverly, MA,
USA) [23]. The unmethylated (negative) control DNA was prepared
by nested whole genome ampliﬁcation of the same DNA sample
using phi29 DNA polymerase (GenomiPhi V2 DNA Ampliﬁcation
Kit, Illustra, GE Healthcare, Buckinghamshire, HP7 9NA, UK) [24].
When MSP using both Um and U primer sets worked well for
control samples but not for a testing sample, the result was cate-
gorized as noninformative.
2.4. Statistical analysis
Fisher's exact test was applied to analyze the results of differ-
ences between different testing groups. Values of p < 0.05 were
considered statistically signiﬁcant.
3. Results
One sample in the SCC group failed in the MSP ampliﬁcation for
all four genes using both Um andM primer sets. All 11 samples with
HSIL were informative for the four genes. Three samples with SCIS
and two with SCC were informative for only three genes, including
one which failed for GSTP1, two for PTGS2, and another two for
RARB as shown in Table 2. Notably, the storage time of all those
parafﬁn-embedded tissues selected for DNA isolation was 10 years.
Compared with the samples with HSIL, failure of MSP ampliﬁcation
seemed to occurmore often in samples with SCIS (3/20) and SCC (3/
15).
The MSP results of all informative samples that showed a pos-
itive ﬁnding for promoter methylation for one or more of the four
genes are depicted in Fig. 1. Table 2 shows the frequencies of the
four genes with promoter methylation detected, either individually
or in different combinations, in the three groups of samples.
Remarkably, among all samples with informative results, none of
the four genes exhibited a detection rate  60%, the preliminary
criteria for acceptance as a promising candidate.Table 2
Detection rates of promoter methylation of four genes using methylation-speciﬁc
polymerase chain reaction (PCR) in the cervical tissues with lesion at different
stages of squamous cell carcinogenesis.
Gene Total
(n ¼ 46)
HSIL
(n ¼ 11)
SCIS
(n ¼ 20)
SCC
(n ¼ 15)
p*
APC 4/46 (8.7) 0/11 (0) 1/20 (5.0) 3/15 (20.0) 0.197
GSTP1 1/45 (2.2) 0/11 (0) 0/20 (0) 1/14 (7.1) 0.556
PTGS2 4/44 (9.1) 1/11 (9.1) 2/18 (11.1) 1/15 (6.7) > 0.99
RARB 6/44 (13.6) 2/11 (18.2) 0/19 (0) 4/14 (28.6) 0.027
Any gene 15/46 (32.6) 3/11 (27.2) 3/20 (15.0) 9/15 (60.0) 0.025
APCþPTGS2þRARB 14/46 (30.4) 3/11 (27.2) 3/20 (15.0) 8/15 (53.3) 0.062
APCþPTGS2 8/46 (17.4) 1/11 (9.1) 3/20 (15.0) 4/15 (26.6) 0.546
PTGS2þRARB 10/46 (21.7) 3/11 (27.2) 2/19 (10.5) 5/15 (33.3) 0.270
Data are presented as n/N (%).
*p value determined using Fisher's exact test.
APC¼ adenomatous polyposis coli; GSTP1¼ glutathione S-transferase; HSIL¼ high-
grade squamous intraepithelial lesion; PTGS2 ¼ prostaglandin-endoperoxide syn-
thase 2; RARB ¼ retinoic acid receptor beta; SCC ¼ squamous cell carcinoma,
pi-class; SCIS ¼ squamous cell carcinoma in situ.There were two other signiﬁcant ﬁndings. One was that the
detection rate of one or more genes with promoter methylation in
the SCC group (60.0%, 9/15) was signiﬁcantly higher than those in
the HSIL (27.2%, 3/11) and SCIS (15.0%, 3/20) groups (p¼ 0.025). The
other ﬁnding was that the detection rate of methylated RARB in the
SCC group (28.6%, 4/14) was signiﬁcantly higher than those in the
HSIL (18.2%, 2/11) and SCIS (0%, 0/19) groups (p ¼ 0.027).
4. Discussion
One SCC sample among the 47 samples examined in this study
failed in MSP ampliﬁcation of all four genes. Five of the remaining
46 samples were noninformative for one gene, including one SCC
sample with failed analysis of GSTP1, two SCIS samples with failed
analysis of PTGS2, and one each of SCIS and SCC sample with failed
analysis of RARB, as shown in Table 2. It is of note that the chro-
mosomal loci of GSTP1, PTGS2, and RARBwere 11q13,1q25.2-q25.3,
and 3p24.2, respectively. The failure rates of MSP ampliﬁcation
seemed to be higher in the SCIS and SCC samples than the HSIL
samples. This phenomenon may be partly due to chromosomal
deletions that often occur during progression of most cancers [25].
In this ﬁrst-stage study of a limited number of samples, there
were two signiﬁcant ﬁndings. Onewas that the overall frequency of
the promoter methylation detectable in the four genes was signif-
icantly higher in the SCC group than in the HSIL and SCIS groups
(p ¼ 0.025). This is consistent with a well-demonstrated phenom-
enon in human cancers, i.e., the overall number of methylated
tumor-related genes often increases gradually along the course of
tumor progression [8]. Another signiﬁcant ﬁnding was that meth-
ylated RARB occurred signiﬁcantly more frequently in the SCC
group than in the other two groups (p ¼ 0.027). These results are
compatible with those found in another study that suggested RARB
methylation seems to be a prognostic factor in cervical carcino-
genesis [26].
RARB is the only one of the three isoforms (alpha, beta, and
gamma) of the nuclear retinoic acid receptor that plays a central
role in growth regulation of epithelial cells and related tumori-
genesis [27]. The data collected in the PubMeth website revealed
that RARB methylation occurs frequently in SCCs arising from the
skin and oral cavity, with reported frequencies ranging from 60% to
80% [14]. The highest frequency of methylated RARB detected in
this study was in the SCC group, 28.6% (4/14), which is consistent
with results from other studies of cervical cancers, with reported
frequencies ranging from 26% to 54% [14e16,18e20].
PTGS2, also called cyclooxygenase-2, is responsible for the
prostanoid biosynthesis involved in inﬂammation andmitogenesis/
carcinogenesis, and is presumably inactivated in apoptosis [28].
Data from several large studies collected in the PubMeth website
revealed that PTGS2 methylation is highly prevalent in cancers
arising from the breast, prostate, and urinary bladder, with re-
ported frequencies ranging from 60% to 80% [14]. The frequencies of
methylated PTGS2 detected in the three sample groups in this study
did not differ signiﬁcantly, and ranged from 6.7% to 11.1% (Table 2).
Only one study has reported cervical SCCs with PTGS2 methylation
of 6.7% (1/15) [17].
APC is a well-characterized tumor suppressor involved in
downregulating Wnt/beta-catenin signaling and is central to
development and the mature organism. Initially identiﬁed in
colorectal cancer, APC is inactivated in various malignancies by
genetic and epigenetic mechanisms [14,29]. Data from several large
studies collected in the PubMeth website revealed that APC
methylation is highly prevalent in cancers arising from the
esophagus and stomach, with reported frequencies ranging from
60% to 80% [14]. The highest detection rate among the three sample
groups in this study was 20% (3/15) in the SCC group. The
Fig. 1. Promoter methylation status of four cancer-related genes determined with methylation-speciﬁc polymerase chain reaction (MSP). APC ¼ adenomatous polyposis coli;
C1eC6 ¼ samples with early-stage squamous cell carcinoma; GSTP1 ¼ glutathione S-transferase, pi-class; H1eH3 ¼ samples with high-grade squamous intraepithelial lesions;
M ¼MSP using methylated primers; m ¼ size markers; PTGS2 ¼ prostaglandin-endoperoxide synthase 2; RARB ¼ retinoic acid receptor beta; S1eS3 ¼ samples with squamous cell
carcinoma in situ; Um ¼ MSP using unmethylated primers; (þ) ¼ methylated positive control; () ¼ unmethylated negative control.
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ranged from 16% to 55% [14,15,17].
GSTP1 is an isoform of the GSTs, a major group of detoxiﬁcation
enzymes. These isoenzymes contribute to resistance to carcino-
gens, antitumor drugs, environmental pollutants, and products of
oxidative stress [30]. Data from several large studies in the Pub-
Meth website revealed that GSTP1methylation is highly prevalent
in prostate cancers, with reported frequencies > 85% [14]. However,
among the 45 samples with informative MSP results in the present
study (Table 2), only one sample in the SCC group was positive for
GSTP1 methylation. The reported frequencies of cervical SCCs in
other studies varied from 0% to 21% [15e17,20].
In conclusion, the aim of this ﬁrst-stage study was to assess if
the promoter methylation of four genes, APC, GSTP1, PTGS2, and
RARB, could be sensitive markers in the detection of HSIL, SCIS, or
early SCC in cervical tissues. MSP analysis of 46 samples revealed
that none of these four genes exhibited a detection rate  the
deﬁned criteria, 60%. Therefore, they are not ideal candidate genes
for further evaluation in a second-stage study.
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